Neumora Therapeutics (NMRA) Assets (2022 - 2026)
Neumora Therapeutics (NMRA) posted quarterly Assets of $153.9 million for Q1 2026, down 40.07% year-over-year from $256.7 million in Q1 2025, and down 19.46% quarter-over-quarter from $191.0 million in Q4 2025.
Neumora Therapeutics (NMRA) Assets (2022 - 2026) Analysis & Trends
Neumora Therapeutics' Assets history runs 5 years deep, the most recent figure standing at $153.9 million for Q1 2026.
- In Q1 2026, Assets fell 40.07% year-over-year to $153.9 million; the TTM figure through Mar 2026 stood at $153.9 million (down 40.07% YoY), while the FY2025 annual figure was $191.0 million, down 39.73% from the prior year.
- Assets for Q1 2026 stood at $153.9 million, down from $191.0 million in the prior quarter.
- The five-year high for Assets was $544.7 million in Q3 2023, with the low at $153.9 million in Q1 2026.
- The 5-year median for Assets is $334.8 million (2024), against an average of $332.9 million.
- The sharpest annual moves came in 2023 and 2025: Assets advanced 16.41% in 2023, then sank 49.56% in 2025.
- Neumora Therapeutics' Assets stood at $426.2 million in 2022, then climbed by 16.41% to $496.2 million in 2023, then sank by 36.12% to $317.0 million in 2024, then sank by 39.73% to $191.0 million in 2025, then decreased by 19.46% to $153.9 million in 2026.
- Business Quant data shows NMRA's Assets at $153.9 million in Q1 2026, $191.0 million in Q4 2025, and $177.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 10.03 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.32 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 9.18 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 15.59 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.56 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.10 Bn |
| 10 | Neumora Therapeutics | 296.45 Mn | 296.45 Mn | - | 153.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 153.88 Mn |
| Dec 31, 2025 | 191.05 Mn |
| Sep 30, 2025 | 177.83 Mn |
| Jun 30, 2025 | 223.83 Mn |
| Mar 31, 2025 | 256.75 Mn |
| Dec 31, 2024 | 316.97 Mn |
| Sep 30, 2024 | 352.54 Mn |
| Jun 30, 2024 | 404.47 Mn |
| Mar 31, 2024 | 450.21 Mn |
| Dec 31, 2023 | 496.20 Mn |
| Sep 30, 2023 | 544.75 Mn |
| Dec 31, 2022 | 426.23 Mn |